ASX ANNOUNCEMENT

6 February 2025

LGP completes Health House acquisition





Little Green Pharma Ltd (ASX: LGP)("**LGP**" or the "**Company**") is pleased to announce it has successfully completed the acquisition of HHI (Australia) Pty Ltd, the owner of the Health House medicinal cannabis distribution business ("**Health House**").

As part of the acquisition, LGP has made the first payment of \$171,000 towards the estimated \$300,000 cash consideration, with the balance amount to be paid in 40 days following the determination of Health House's 31 January 2025 working capital position.

LGP considers this transaction to be an exceptional value acquisition and an important step in the Company's long-term strategy of vertical integration and disciplined acquisition, particularly amid the ongoing restructuring of the Australian medicinal cannabis industry.

LGP CEO Paul Long commented:

"We are delighted to complete the acquisition of Health House, a long-term distribution partner of LGP. This transaction aligns with our vertical integration and acquisition strategy and secures us a great business with a proven track record. Most importantly, we look forward to welcoming the talented Health House team into LGP and working together to ensure a seamless transition. Their expertise and industry relationships will be invaluable as we continue to grow our business in an evolving market."



ENDS BY ORDER OF THE BOARD

Alistair Warren Company Secretary



For further information please contact:

Alistair Warren Company Secretary Little Green Pharma E: cosec@lgp.global T: +618 6280 0050 Paul Long Chief Executive Officer Little Green Pharma E: p.long@lgp.global T: +61 8 6280 0050

About Little Green Pharma and Reset Mind Sciences

Little Green Pharma Group is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing, distribution and clinical services.

The Company has three global production sites for the manufacture of its own-branded and white-label ranges of medicinal cannabis and psychedelic products, being a Danish glasshouse facility, a West Australian indoor craft production facility with a combined nameplate capacity of 30 tonnes of cannabis biomass per annum, and a combined psychedelics clinic, head office and therapeutic goods manufacturing facility located in Western Australia. The Company also has an Australian medicinal cannabis distribution business.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets and delivers psychedelic assisted psychotherapy services via its wholly-owned Reset Mind Sciences business.

The Company has a strong focus on patient access in global medicinal cannabis markets and the Australian psychedelic market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: <u>www.littlegreenpharma.com</u> and Reset Mind Sciences: <u>https://www.resetmind.com.au/</u>

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.investorcentre.com/au

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: https://investlittlegreenpharma.com/site/contact/newsletter-sign-up